Current Issues of Antiviral Therapy of Arvi and Influenza in Military Units

Abstract

Conducting preventive medical and epidemiological measures for influenza and ARVI in closed military units, including on ships, vessels and auxiliary units of the Navy, is a factor of increasing the combat effectiveness of forces of the Russian Army. In the structure of total morbidity of military personnel, acute respiratory viral infections account for 35–50%, however, during the young military reinforcement, the incidence of these infections in combination with community-acquired pneumonia can reach 70–80%. The risk of exceeding the epidemiological threshold for respiratory tract infections, the etiological basis of which is viral aggression, is especially important in newly formed military contingents, for units participating in local military conflicts and peacekeeping operations, as well as with a new recruitment of cadets at training centers. The use of non-specific antiviral drugs based on exogenous recombinant interferon -2b is one of the conditions for adequate prevention of influenza and ARVI in closed military units. The paper presents the results from the analysis of publications on the effectiveness and Viferon® safety in the treatment of influenza and ARVI. Viferon is a preparation of recombinant human interferon -2b with a complex of antioxidants in various dosage forms, used in the treatment and prevention of acute respiratory viral infections and influenza. Use of Viferon in various dosage forms is a reliable method of prevention and treatment of influenza and other acute respiratory viral infections in military forces, including on ships, vessels and auxiliary units of the Navy, at risk of emergency epidemiological situations due to ARVI and influenza, in conditions of limited contingent.